Search

[Re-188]Rhenium sulfide suspension was prepared by the reaction of Na2S2O3 and KReO4 containing (NaReO4)-Re-188 in acid solution and assessed for its applicability in tumor treatment by the techniques of radioisotope interventional therapy. The reaction conditions such as the concentration ratio of Na2S2O3, to KReO4, heating time, ultrasonic time were optimized. The radiochemical yield of [Re-188]Rhenium sulfide suspension is more than 96% and in vitro stability studies demonstrated that more than 99% of the 188Re remained in sulfide form over a 72hrs period. The main particle size after various ultrasonic times is 1-5 mu m. [Re-188]Rhenium sulfide suspension was injected into tumors and the tumor-bearing mice were killed after some time to determine the retention of Re-188 in tumor and the leakage to different organs by gamma counter. The mean retention percentages of Re-188 in tumors were 83.08 +/- 13.71%, 83.92 +/- 9.79%, 80.23 +/- 3.82% and 78.75 +/- 3.02% at Ih, 24, 48 and 72hrs respectively. After 72hrs the highest activity outside the tumors was in the liver, spleen and the kidneys. Our preliminary results indicated that [Re-188]Rhenium sulfide suspension may be an effective radiopharmaceutical for tumor treatment by the techniques of radioisotope interventional therapy.

A separation procedure of trace platinum from large amounts of mercury and other interfering elements is described. After irradiation, the HgO target was dissolved in concentrated HCl solution. The thallium fraction was removed by solvent extraction with ether. In the aqueous phase after extraction the radioisotope of platinum produced by irradiation was precipitated as (NH4)2PtCl6 by adding a saturated solution of NH4Cl in the presence of H2PtCl6·6H2O as stable carrier. The decontamination factor of mercury, gold and thallium and the recovery of platinum in the process of separation are satisfactory.